

Human Papillomavirus (HPV) Vaccines Session

Joseph A. Bocchini, Jr., MD
Chair, ACIP HPV Vaccines Work Group

Advisory Committee on Immunization Practices
June 25, 2015

9-valent HPV vaccine

- ❑ Licensed by FDA on December 10, 2014
- ❑ Considered by ACIP at February 2015 meeting
 - Short ACIP meeting due to CDC closure
 - Vote and MMWR Policy Note published on March 27
 - One issue not considered – additional vaccination for those who completed an HPV vaccination series

Morbidity and Mortality Weekly Report

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices

Emiko Petrosky, MD^{1,2}, Joseph A. Bocchini Jr, MD³, Susan Hariri, PhD², Harrell Chesson, PhD², C. Robinette Curtis, MD⁴, Mona Saraiya, MD⁵, Elizabeth R. Unger, PhD, MD⁶, Lauri E. Markowitz, MD² (Author affiliations at end of text)

During its February 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended 9-valent human papillomavirus (HPV) vaccine (9vHPV) (Gardasil 9, Merck and Co., Inc.) as one of three HPV vaccines that can be used for routine vaccination (Table 1). HPV vaccine is recom-

(2vHPV), which contains HPV 16, 18 VLPs, is licensed for use in females (1). This report summarizes evidence considered by ACIP in recommending 9vHPV as one of three HPV vaccines that can be used for vaccination and provides recommendations for vaccine use.

9-valent HPV vaccine presentations to ACIP

- Epidemiology and burden of disease due to HPV types
February 2014
- Clinical trial data
February 2014, June 2014, October 2014
- GRADE
October 2014
- Health economic analysis
October 2014, February 2015
- Discussion of policy options
October 2014, February 2015
- 9-valent HPV vaccine recommendations and vote
February 2015

ACIP HPV Vaccines Work Group

- ❑ Reviewed evidence for additional 9-valent HPV vaccination
 - Type-specific disease
 - Clinical trial data
 - Cost effectiveness
- ❑ Discussed additional transition issues
- ❑ Considerations for guidance

Outline of June 2015 HPV session

- ❑ Background, 9vHPV transition, clinical trial data
 - Dr. Lauri Markowitz, NCHHSTP, CDC
- ❑ Impact and cost effectiveness of additional vaccination
 - Dr. Harrell Chesson, NCHHSTP, CDC
- ❑ Considerations and discussion
 - Dr. Lauri Markowitz, NCHHSTP, CDC

ACIP HPV Vaccines Work Group members

ACIP Members

Joseph Bocchini (WG chair)
Allison Kempe
Jose Romero
Laura Riley

Ex Officio Members

Carolyn Deal (NIH)
Bruce Gellin (NVPO)
Sixun Yang (FDA)
Jeff Roberts (FDA)

CDC Lead

Lauri Markowitz

Liaison Representatives

Sandra Fryhofer (ACP)
Amy Middleman (SAHM)
James Turner (ACHA)
Patricia Whitley-Williams (NMA)
Rodney Willoughby (AAP)
Jane Zucker (AIM)
Margo Savoy (AAFP)
Linda Eckert (ACOG)
Shelley Deeks (NACCI)

Consultants

Tamera Coyne-Beasley
John Douglas
Janet Englund
Sam Katz
Debbie Saslow (ACS)
Aimee Kreimer (NCI)